Ikena Oncology, Inc. (NASDAQ: IKNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer [Yahoo! Finance]
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum [Yahoo! Finance]